Top Biotech Stocks To Own For 2018

Media coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.1697360590994 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news articles that may have effected Accern’s analysis:

Top Biotech Stocks To Own For 2018: Meridian Bioscience Inc.(VIVO)

Advisors’ Opinion:

  • [By Logan Wallace]

    VIVO (CURRENCY:VIVO) traded down 0.1% against the dollar during the 24 hour period ending at 0:00 AM Eastern on May 8th. In the last seven days, VIVO has traded down 9.4% against the dollar. One VIVO coin can now be bought for about $0.77 or 0.00008506 BTC on major cryptocurrency exchanges including Cryptopia, CryptoBridge and Stocks.Exchange. VIVO has a market cap of $1.41 million and approximately $9,560.00 worth of VIVO was traded on exchanges in the last day.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Biotech Stocks To Own For 2018: SodaStream International Ltd.(SODA)

Advisors’ Opinion:

  • [By Demitrios Kalogeropoulos]

    SodaStream(NASDAQ:SODA) recently announced surprisingly strong first-quarter earnings as sales growth sped up to a 25% pace and profitability improved. The seller of at-home carbonated beverage machines is benefiting from a long-term trend of rising global demand for sparkling water.

  • [By Stephan Byrd]

    SodaStream (NASDAQ:SODA)‘s stock had its “hold” rating reiterated by stock analysts at Jefferies Group in a research note issued to investors on Wednesday. They currently have a $82.00 price target on the stock. Jefferies Group’s target price suggests a potential downside of 5.87% from the stock’s current price. Jefferies Group also issued estimates for SodaStream’s Q2 2018 earnings at $0.74 EPS, FY2018 earnings at $3.55 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.79 EPS and Q1 2020 earnings at $0.89 EPS.

  • [By Chris Lange]

    SodaStream International Ltd. (NASDAQ: SODA) reported its fourth-quarter financial results before the markets opened on Wednesday. The company said that it had $1.13 in earnings per share (EPS) on $157.7 million in revenue, which compares with consensus estimates from Thomson Reuters of $0.80 in EPS on revenue of $151.57 million. In the same period of last year, it said it had EPS of $0.71 and $131.8 million in revenue.

  • [By Jeremy Bowman]

    I’m talking aboutSodaStream International(NASDAQ:SODA), of course, the Israeli do-it-yourself sparkling water specialist. Shares of SodaStream sold off following the earnings report on Wednesday even though the company once again beat earnings and revenue estimates. Below were the key figures from the first-quarter report.

Top Biotech Stocks To Own For 2018: WEC Energy Group, Inc.(WEC)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on WEC Energy Group (WEC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on WEC Energy Group (WEC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com